340B program legal battle

If you've never heard of the 340B Drug Pricing Program, you're not alone. Most patients who benefit from it have no idea it exists, they just notice their prescription costs less at certain hospitals and clinics than it would elsewhere.

That quiet benefit is now caught in one of the messier legal fights in American healthcare policy. Multiple lawsuits, a circuit split between federal appeals courts, and a shifting federal position have all landed on this program at once. Here's what's actually going on.

What 340B Was Built to Do

Congress created the 340B program in 1992. The idea was straightforward: require drug manufacturers to sell outpatient medications at a discount to hospitals and clinics that serve a disproportionate share of low-income or uninsured patients, in exchange for those manufacturers' drugs being covered under Medicaid.

Over the decades, the program grew well beyond its original scope. Eligible hospitals expanded, contract pharmacy arrangements (where a hospital partners with an outside pharmacy to dispense 340B-discounted drugs) became common, and the dollar value flowing through the program grew into a genuinely large chunk of the pharmaceutical market. That growth is a big part of why manufacturers are fighting back now.

Why Manufacturers Started Pushing Back

Drug manufacturers have been restricting access to 340B pricing at contract pharmacies since roughly 2020, arguing the arrangement has drifted far from its original safety-net purpose and is cutting into their margins in ways Congress never intended. Hospitals and community health centers, for their part, argue those restrictions choke off funding that supports care for exactly the patients the program was designed to protect.

In clinical practice, this tension is often invisible to the patient sitting in a hospital pharmacy line, but it's very visible to hospital finance departments, where 340B revenue can be a meaningful part of the budget for services that don't otherwise pay for themselves, things like uncompensated care and community health programs.

Where the Legal Fight Actually Stands

This is where it gets genuinely complicated, so bear with the short version.

States started passing laws to protect contract pharmacy access, and manufacturers responded by suing, arguing these state laws are preempted by federal statute. The result is a fractured legal map rather than one clear answer. The Fifth Circuit upheld Mississippi's protective law in 2025. The Fourth Circuit went the other way in early 2026, blocking a similar law in West Virginia on preemption grounds. That's a circuit split, meaning federal appeals courts disagree, and it usually signals a fight that could eventually reach the Supreme Court.

Washington state passed its own contract pharmacy protection law in 2026, and drug manufacturers, including AbbVie, Novartis, and the industry group PhRMA, immediately sued to block it. A federal district court denied their request for a preliminary injunction in June 2026, so the law took effect, though the underlying lawsuit isn't resolved.

Separately, federal health regulators have been through their own back-and-forth. HHS tried to pilot a rebate-based model for 340B pricing, was blocked by a federal appeals court in early 2026, withdrew the pilot, and has since floated a revised version. The Justice Department also filed briefs in early 2026 siding with drug manufacturers in some of these state-law disputes, a notable shift in the federal government's posture on the issue.

Why This Actually Matters Beyond the Courtroom

It's easy to read all of this as lawyers arguing over money, and to some extent, it is. But the outcome affects whether safety-net hospitals and community clinics can keep offering the discounted-drug pricing that lets them serve patients who can't otherwise afford their medications.

If manufacturer restrictions on contract pharmacies expand, some patients could see fewer nearby pharmacy options for accessing 340B-priced drugs, or hospitals could see enough revenue pressure that it affects the broader services they offer. If state protective laws hold up instead, that pressure eases, at least in the states with those laws on the books.

None of this is settled yet. Anyone following it closely should expect more court rulings, not fewer, over the rest of 2026.

A Fair Caveat

This is genuinely contested legal and regulatory territory, and reasonable people, including federal judges, disagree on how existing law applies. Nothing above should be read as legal advice for a hospital, pharmacy, or manufacturer navigating compliance, and patients with specific concerns about drug pricing at a particular hospital should ask that hospital's billing or patient assistance office directly rather than relying on general commentary like this.